Factor Model (net +0.3)
Factor Model
net +0.3
Est. Revisions
-0.6
Insider Activity
+0.0
Momentum
+0.0
Analyst Rev.
+1.0
Narrative Gap
+0.0
Analysis pending — waiting for first signal cycle.
Evidence
Updated Friday
Genmab A/S (GMAB) Rating Lifted by Goldman Sachs on Strong 2026 Catalyst Outlook
yahoo-finance
Fundamentals & Data ▾
Genmab A/S
Healthcare · Biotechnology
Mkt Cap
$17B
P/E
17.5 fwd 15.2
Beta
0.74
52w Range
$18.89 - $35.43
Short Interest
8.6M 1.41%
Days to Cover
5.3 -1%
Technicals
downtrend
from 52w Hi
-5.9%
1w return
-5.9%
EPS Estimate
$0.16
+18.5% 30d
1up / 0dn
Est. Dispersion
0%
1 analysts
Analyst Target
$38
$30 - $48
Options P/C
9.51
Fund Convergence
strong
Renaissance, Two Sigma, Citadel
Financials
Revenue
$1.1B +42% YoY
FCF
$288M
Gross Margin
92%
Op Margin
23%
Momentum:
decelerating
Top Holders
Renaissance
$108M
Two Sigma
$10M
Citadel
$2M
2 signals · latest Updated Friday
Get alerted when GMAB changes direction
We'll email you when our AI detects a shift — reversals, insider clusters, filing red flags.